1 / 25

GATCACTGGCATGCATCGATCGACTGACTGCGGCATGCGCG ATCGACTGGCGATCAAACAGTCACGCGCATCGATCGACTGA

GATCACTGGCATGCATCGATCGACTGACTGCGGCATGCGCG ATCGACTGGCGATCAAACAGTCACGCGCATCGATCGACTGA GATCGCGGCATCGCGACGCGGATAAATACGAGCACTACAAA TGACTACGGGATTTTACGCGCGATACGACTGACTGACTAGC GATCACTGGCATGCATCGATCGACTGACTGCGGCATGCGCG ATCGACTGGCGATCAAACAGTCACGCGCATCGATCGACTGA

dori
Télécharger la présentation

GATCACTGGCATGCATCGATCGACTGACTGCGGCATGCGCG ATCGACTGGCGATCAAACAGTCACGCGCATCGATCGACTGA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GATCACTGGCATGCATCGATCGACTGACTGCGGCATGCGCG ATCGACTGGCGATCAAACAGTCACGCGCATCGATCGACTGA GATCGCGGCATCGCGACGCGGATAAATACGAGCACTACAAA TGACTACGGGATTTTACGCGCGATACGACTGACTGACTAGC GATCACTGGCATGCATCGATCGACTGACTGCGGCATGCGCG ATCGACTGGCGATCAAACAGTCACGCGCATCGATCGACTGA GATCGCGGCATCGCGACGCGGATAAATACGAGCACTACAAA TGACTACGGGATTTTACGCGCGATACGACTGACTGACTAGC TGACGATCGAGAGACTCG01010001010101000101010101001 0010101010100000011110101111101001010101000111011101 0111101101010111001010101000111010101001100101110101 0111010010001010100011110101000010101010100010100011 0010101000101011110101000100100100101010001000001011 0010101010100000011110101111101001010101000111011101 0111101101010111001010101000111010101001100101110101 0111010010001010100011110101000010101010100010100011 0010101000101011110101000100100100101010001000001011 0101001010000101111101001010010101011101010010101001 LINCS Fall Consortia Meeting Broad Institute U54 Team Todd Golub, co-PI Wendy Winckler, co-PI Aravind Subramanian, Team Leader October 27, 2011

  2. BASIC DISCOVERIES THERAPEUTIC IMPACT CONNECTIONS PATHWAYS DISEASE STATES TOOL COMPOUNDS GENETIC GWAS TCGA RNAi DRUGS DIAG- NOSTICS CHEMICAL SCREENS NAT’L PRODUCTS SLOW (SOME NEVER START) DOES NOT SCALE NO LEVERAGE

  3. LINCS as a Solution • perturbations scalable to genome • high information content read-outs (e.g. gene expression) • inexpensive • mechanism to query database

  4. Toward a reduced representation of the transcriptome gene expression is correlated samples genes

  5. Reduced Representation of Transcriptome reduced representation transcriptome ‘landmarks’ computational inference model genome-wide expression profile 80% ~ 100,000 profiles % connections 1000 A. Subramanian, R. Narayan number of landmarks measured

  6. Luminex Beads (500 colors, 2 genes/color) 001 1000-plex Luminex bead profiling 5' AAAA 3' RT 3' 5' 5'-PO4 | 3' TTTT ligation 5' 5' PCR hybridization Reagent cost: $3/sample

  7. Validation of L1000 approach Gene-level validation 92% R2 > 0.6 Similar to AFFX vs ILMN 1000-plex-Luminex Affymetrix

  8. Putting it all together Illustration: Bang Wong

  9. Cell Types GTEx Primary hTERT-immortalized cells Patient-derived iPS cells* Banked primary cells* (T-cells, macrophages, hepatocytes, myocytes, adipocytes) Cancer cell lines * in assay optimization

  10. 2-3 weeks 3-4 weeks 4-6weeks Reprogramming [Oct4, Sox2, Klf4, Myc] Cell Repository (e.g. Coriell) Neural Differentiation Astrocyte somatic cell isolation Oligo- dendrocyte Neural progenitors fibroblasts Neuron

  11. Perturbagens Small-molecules (n=4,000) Genes (n=3,000)

  12. Automated Quality Control Measures Overall failure rate ~ 8%

  13. LINCS Proposal (~ 600,000 profiles) • 4,000 compounds • 1,300 off-patent FDA-approved drugs • 700 bioactive tool compounds • 2,000 screening hits (MLPCN + others) • 2,000 genes (shRNA + cDNA) • known targets of FDA-approved drugs (n=150) • drug-target pathway members (n=750) • candidate disease genes (n=600) • community nominations (n=500) • 20 cell lines • emphasis on reproducibility and availability • cancer and primary, non-cancer • some ‘doubling down’ to assess intra-lineage diversity

  14. Progress to date http://www.broadinstitute.org/lincs_beta/ proposed actual DATA RELEASE (BETA) projected

  15. Signature of p53 ORF p53 vs. empty vector • p53 is NOT a Landmark Gene • p53 pathway is #1 pathway of 512 in MSigDB P < 0.001 Ramnik Xavier

  16. Making connections in primary macrophages NF-kB pathway genes (all INFERRED) pathway rank: 1/512 LPS pathways curated from literature (n=512) Jens Lohr

  17. Prioritizing human genetics candidates Ramnik Xavier, MGH

  18. Signatures of genetic variants connect to disease genesets Ramnik Xavier, MGH

  19. Disease variants connect to pathways e.g. CD40 to ATG16L1 (both regulators of autophagy) Ramnik Xavier, MGH

  20. ERG transcription factor important in hematopoietic stem cells, prostate cancer ERG-binding small-molecules

  21. Defining a gene expression signature of ERG activity integrating experimental and clinical data Gain of Function: Primary prostate + hTERT +ST +AR +/-ERG • Loss of Function: VCaP cells +/- ERG shRNA 120 • Patient Samples: Physician’s Health Study

  22. 3/69 ERG-binders inhibit ERG gene expression program

  23. L1000 as primary small-molecule screen read-out 12,985 compounds screened for ERG signature

  24. Analytical and software challenges • Infrastructure: data and compute server • Optimization of connectivity metrics and statistics • Optimization of inference models (context-aware) • UI: query tools and results visualization • Addressing off-target effects of perturbagens

  25. Aravind Subramanian Wendy Winckler Justin Lamb Computational Rajiv Narayan Josh Gould RNAi Platform Chemical Biology Platform Genetic Analysis Platform Broad Program Scientists Laboratory Dave Peck Willis Reed-Button XiaodongLu

More Related